Overview


Clinical Trials

Severe CHD

Wound Healing

 PAD


Pre-Clinical Research
Scientific Reports

   
CVBT Pre-Clinical Research  
 


We are now working to investigate FGF-1 for many different applications, and have initiated pre-clinical testing for the following:

·   FGF-1 and Stroke – the goal of our pre-clinical research is to assess the effects of our drug candidate, CVBT-141F, in reducing brain damage due to stroke
· FGF-1 and Osteoporosis – to date we have seen positive pre-clinical results of the effects of our drug candidate, CVBT-141G, in an animal model of bone growth
· Lumbar Ischemia – the study is being conducted by Vance Gardner, M.D. and the Orthopaedic Education and Research Institute of Southern California

 

 

Use of this site constitutes agreement to our Terms and Conditions
and Privacy Policy. Site Design and Contents © 2008 CardioVascular BioTherapeutics, Inc. All Rights Reserved.

Some content on this site requires the free Adobe Reader.









 

7/1/2008
Dutton Associates Announces Investment Opinion: CardioVascular BioTherapeutics Maintained At Neutral Rating By Dutton Associates


6/10/2008
CVBT Inks Third Clinical Development Agreement


5/22/2008
Dr. Christopher Moore to Form ProDerm LP to Fund CVBT Wound Healing Trial


4/24/2008
CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership